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Metastases are the main cause of morbidity and mortality in breast cancer patients. 35
Their efficient dissemination is directly linked to the invasive behaviour of cancer cells 36 (Friedl and Wolf 2003) , which requires the cells to destroy and reorganize the extra-cellular 37 matrix as well as the capacity to migrate. This is a complex process involving many players 38 among which NFAT transcription factors, especially NFAT1, are critical (Jauliac et al. 2002; 39 Yoeli-Lerner et al. 2005) . 40
The family of NFAT transcription factors comprises five genes (NFAT1 to 5). NFAT1, 41 NFAT2, NFAT3 and NFAT4 were first identified as T cell transcription factors that bind IL-2 42 promoter after cell activation (Shaw et al. 1988 ), while NFAT5 is induced by osmotic stress 43 In line with this duality of function, we have reported that NFAT3 is specifically expressed in 53 oestrogen receptor -positive breast cancer cells and, contrary to NFAT1 and NFAT5, 54 inhibits these cells' motility by blocking LCN2 (Lipocalin 2) gene expression (Fougère et al. 55 2010) . 56 LCN2 is a secreted protein of the Lipocalin family (Flower 1996) , the high expression 57
of which is associated with malignancy in different types of cancers (Bartsch and Tschesche 58 samples, where it might regulate cancer cell migration (Michaelson et al. 2005 ; Willis et al. 71 2008) . Indeed, the positive role of the TWEAK/TWEAKR axis on cancer cell migration has 72 been reported (Dai et al. 2009 ; Tran et al. 2006 ), but there are also reports that TWEAK 73 inhibits migration (Meighan-Mantha et al. 1999) . Recently, a preclinical study has shown that 74 a humanized antibody directed against the TWEAKR can mediate anti-tumour effects by 75 signalling through TWEAKR (Culp et al. 2010) . 76
Here, we report that signalling through NFAT1 up-regulates LCN2 expression by 77 NFAT1 direct binding on LCN2 promoter and that LCN2 is required for NFAT1 to foster 78 breast cancer cell invasion. Downstream of NFAT1 and LCN2, we identify the 79 TWEAKR/TWEAK axis as a key player for regulating the invasive process, and show that, 80 depending on LCN2 expression level, TWEAK displays both anti-invasive and pro-invasive 81 functions. Thus, we uncover a novel NFAT1/LCN2/TWEAKR/TWEAK axis critical to 82 regulate breast cancer cell invasion. 83
84
Results 85 86
NFAT1 up-regulates LCN2 expression in breast cancer cells 87
Having recently shown that NFAT3 inhibits LCN2 transcription in breast cancer cells 88 (Fougère et al., 2010) , we evaluated here the effect of NFAT1 on LCN2 expression. However, 89 since NFAT1 and LCN2 proteins are essentially not expressed in oestrogen receptor-positive 90 (ERA + ) cancer cells (Fougère et al., 2010) , this was done only using ERA-negative (ERA -) 91 cells in which, contrary to NFAT3, NFAT1 and LCN2 are highly expressed. First, we used 92 NFAT1-specific siRNA to silence endogenous NFAT1 in MDA-MB-231, which reduced its 93 expression by 90% ( Fig. 1A , right panel) without affecting that of NFAT5 or NFAT4 (data 94 not shown). NFAT1 silencing (which did not result in cell apoptosis as assayed by annexin V 95 labelling data; not shown) reduced by 5-fold LCN2 mRNA expression relative to control cells 96 To more thoroughly analyse the relationship between LCN2 expression and NFAT1 125 signalling, we investigated the LCN2 promoter region where 6 potential NFAT-binding sites 126 (-881, -522, -501, -441, -409, -142) ( Fig. 2A ) have been identified (Fougère et al. 2010) . 127
Using a Luciferase gene-fused LCN2 promoter, we found that NFAT1 ectopic expression 128 doubled the promoter activity relative to empty vector-transfected cells ( Fig. 2B ). To assess 129 whether endogenous NFAT1 interacted with LCN2 promoter region, chromatin 130 immunoprecipitation (ChIP) was performed in cells treated by control or NFAT1-specific 131 siRNAs: indeed, endogenous NFAT1 bound to LCN2 promoter whereas no significant signal 132 enrichment was noted when NFAT1 was silenced ( Fig. 2C , si ctrl versus si NFAT1). To 133 confirm NFAT1 binding to LCN2 promoter region and determine whether NFAT1 putative 134 binding sites are functional in vivo, we individually mutated each of these. Measurement of 135 Luciferase activity after transient co-transfection of MDA-MB-231 cells with NFAT1 of 136 mutated LCN2 promoter revealed that the -409 binding site was required for NFAT1 to 137 increase transcriptional activity, the -501 and-142 sites being required for LCN2 promoter 138 basal activity ( Fig. 2D ). Electrophoretic mobility shift assays were then performed to confirm 139 that endogenous NFAT1 bound to these identified sites and, indeed, NFAT1 bound to the -140 501, -409, -142 wild-type, but not mutated, binding sites ( Fig. 2E ). NFAT1-specific binding 141 was confirmed by pre-incubating nuclear extracts with an anti-NFAT1 antibody that 142 supershifts the complex NFAT1/probe ( Fig. 2E , arrows). As control, no supershift was 143 induced by pre-incubating nuclear extracts with control IgG. 144
These data demonstrate that endogenous NFAT1 binds directly to the LCN2 promoter 145 -501, -142 sites to modulate its basal expression, and to the -409 site to regulate its inducible 146 expression. 147 148
The NFAT1/LCN2 axis modulates TWEAKR expression 149
To assess the mechanisms by which the NFAT1/LCN2 axis up-regulates breast cancer 150 cell invasion, we used transcriptome analysis of LCN2-specific siRNA-treated MDA-MB-231 151 cells in order to identify genes regulated by LCN2 potentially involved in the invasive 152 capacity. LCN2 silencing impacted 95 genes by at least 1.5 fold (95% confidence level) ( Fig.  153 3A, and Supplementary Table 1 ), which was confirmed by RT-QPCR for most of these (data 154 not shown). Because we have shown that NFAT1 regulates LCN2 expression, we examined 155 whether modifying NFAT1 expression affected any of the 95 LCN2-regulated genes. Indeed, 156 siRNA silencing of NFAT1 reduced expression of two of them: TWEAKR (TNFSFR12A) 157 ( Fig. 3B ) and C6ORF55 (VTA1) (data not shown). Thus, out of the 95 identified genes that 158 putatively could be involved in the invasion process of breast cancer cells, only these two 159 were regulated in the same manner by NFAT1 and LCN2. Silencing VTA1 with siRNA had 160 no effect on cancer cell invasive capacity (data not shown). Because TWEAKR was already 161 known to participate in the motility of different cell types ( These data indicate that TWEAKR is regulated by NFAT1 and LCN2 at the mRNA 168 and protein levels in breast cancer cells. 169 170
Reciprocal regulation of the TWEAKR/TWEAK axis and LCN2 expression 171
In contrast to TWEAKR, silencing or overexpressing LCN2 in MDA-MB-231 cells 172 did not modify mRNA levels of its ligand, TWEAK ( Supplementary Fig. S2A and B), which 173 was indeed not found among the 95 genes identified in Fig. 3A (see Supplementary Table 1) . 174 Nonetheless, when LCN2 or NFAT1 were independently silenced with siRNA directed to 175 either, which reduced their expression by 90%, TWEAK protein levels in cell supernatants 176 increased relative to the control condition ( Fig. 4A ). To validate that TWEAK protein is 177 regulated by LCN2, cells were transiently transfected with a fixed amount of a TWEAK-178 expressing vector and increasing amounts of a LCN2-expressing vector, which resulted in 179 dose-dependent decrease of TWEAK levels (Fig. 4B ). Moreover, TWEAKR depletion by 180 siRNA led to increased TWEAK protein levels without modifying its mRNA expression in 181 MDA-MB-231 and SUM-159-PT cells ( Supplementary Fig. S3 ). 182
Because LCN2 regulated TWEAK protein amount, we verified whether TWEAK or 183 TWEAKR per se affected LCN2 protein levels by transiently transfecting MDA-MB-231 184 cells with siRNA targeting TWEAKR or TWEAK. Indeed, silencing of either led to LCN2 185 level increase and this effect was cumulative ( Fig. 4C ). Moreover, TWEAK and TWEAKR 186 depletion up-regulated LCN2 mRNA expression ( Fig. 4D ), suggesting a transcriptional link. 187
To confirm this link, the cells were pre-treated by a transcriptional inhibitor (actinomycin D), 188 which inhibited LCN2 mRNA increase elicited by TWEAK and TWEAKR depletion. We 189 verified here that silencing TWEAKR and/or TWEAK did not modify cell apoptosis or 190 proliferation ( Supplementary Fig. S4A 
TWEAK increases breast cancer cell invasion independently of the TWEAKR 198
TWEAKR signalling has already been implicated in the invasive process in different 199 cell models. To validate that TWEAKR was involved in the chemotactic invasive capacity of 200 MDA-MB-231 cells, chemoinvasion assays were performed in the presence or not of 201 recombinant TWEAK, whose presence was thus shown to increase invasion ( Fig. 5A ). 202
However, blocking TWEAKR with a specific neutralizing antibody also increased invasion as 203 compared to control IgG, and adding recombinant TWEAK potentiated this effect ( Fig. 5A ), 204 neither of which modifying cell apoptosis or proliferation ( Supplementary Fig. S4B , C). 205
When we repeated the experiment in NFAT1-transfected cells, again pre-treatment with the 206 TWEAKR neutralising antibody enhanced chemoinvasion elicited by NFAT1 ( Fig. 5B) , 207 suggesting that TWEAKR mediates an anti-invasive effect in breast cancer cells in this assay. 208
As a confirmation, we repeated the experiment presented in Fig. 5A by using a siRNA 209 targeting TWEAKR. After verifying that the siRNA actually reduced TWEAKR expression 210 ( Fig. 5C , right panel) and did not affect apoptosis or proliferation ( Supplementary Fig. S4A ), 211 we found again that chemoinvasion increased when TWEAKR was silenced and that this was 212 potentiated by adding recombinant TWEAK ( Fig. 5C , left panel). 213
These findings were surprising in light of the report that, in breast cancer cells, 214 TWEAKR silencing led to loss of invasion potential (Willis et al. 2008) . But in that case the 215 assay (Hauck et al. 2002; Hsia et al. 2003 ) assessed random cell invasion, no chemotactic 216 gradient being used, whereas ours is chemoinvasion assay using conditioned medium from 217 NIH3T3 cells in order to create a chemotactic gradient (Albini and Benelli 2007) . Therefore, 218
we examined if the different assays accounted for the discrepancy. To this end MDA-MB-231 219 cells, transiently transfected with either control or TWEAKR-specific siRNAs, were 220 comparatively assessed in both assays. Data from Fig. S5 indicate that cells were actually less 221 invasive and that TWEAKR silencing inhibited invasion in the radom invasion assay, whereas 222 increased invasion in presence was noted as expected in the chemoinvasion assay. Thus, 223 TWEAKR would differently influence random and directed cell invasion. 224
To evaluate the role of LCN2 in regulating invasion downstream of TWEAK, MDA-225 MB-231 cells were transiently transfected with control or LCN2-specific siRNAs and 226 exposed to recombinant TWEAK. In this case, when LCN2 was silenced, TWEAK no longer 227 increased chemoinvasion ( Fig. 5D ). 228
These data identify TWEAKR as a receptor that antagonizes the chemotactic 229 invasion process of breast cancer cells. Importantly, they indicate that LCN2 is required for 230 TWEAK to increase chemotactic invasion, either directly or via another as yet unidentified 231 receptor different from TWEAKR. 232 233
Depending on LCN2 expression TWEAK displays either anti-and pro-invasive activities 234 in breast cancer cells 235
Inasmuch as TWEAK availability appeared to be regulated by TWEAKR, LCN2 and 236 NFAT1, we more precisely examined the role of TWEAK protein on breast cancer cell 237 invasion. MDA-MB-231 cells were transiently transfected with control siRNA or with 238 siRNAs targeting TWEAKR, LCN2, NFAT1 or TWEAK, alone or in combination ( Fig. 6A ). 239
As shown in Fig. 5C , TWEAKR silencing led to increased chemoinvasion, and either NFAT1 240 ( Fig. 6A , si TWR si NFAT1) or LCN2 ( Fig. 6A , si TWR si LCN2) depletion prevented this 241 increase, demonstrating that LCN2 increased expression elicited by TWEAKR knockdown 242 was responsible for this effect. Indeed, when NFAT1 was silenced, and by consequence 243 LCN2 too, again the increase of chemoinvasion induced by TWEAKR down-regulation was 244 abrogated ( Fig. 6A , si TWR si NFAT1). Since we have shown that TWEAKR depletion 245 induces TWEAK protein up-regulation ( Supplementary Fig. S3 ), we examined whether the 246 latter was involved in this increased invasion. Indeed, when TWEAK was silenced by siRNA 247 together with TWEAKR ( Fig. 6A , si TWR si TW, -), increased invasion was abolished but it 248 was rescued by adding back recombinant TWEAK (Fig. 6A , si TWR si TW, +). The same 249 results were obtained with SUM-159-PT cells ( Supplementary Fig. S6 ). 250
These data indicate that TWEAK protein up-regulation is critical to increase invasion 251 and entails the presence of LCN2. 252
Interestingly, we have shown that, like TWEAKR down-regulation, that of either 253 LCN2 or NFAT1 induced increased TWEAK protein levels, albeit without increasing but 254 rather inhibiting chemoinvasion. Therefore, we hypothesized that, beside its pro-invasive role, 255 Supplementary Fig. S6 ). 270
Altogether, these data demonstrate that, beside its pro-invasive action, TWEAK has an 271 anti-invasive action in breast cancer cells in the absence of LCN2. Thus, TWEAK is a pro-272 invasive factor in breast cancer cells in presence of LCN2 and anti-invasive in its absence. Recently, a new layer of complexity has been added by the observation that among the 282 members of the NFAT family, NFAT3 -expressed in less aggressive oestrogen receptor -283 positive breast cancer cells-has anti-migratory and anti-invasive actions in contrast to 284 NFAT1 and NFAT5. One mechanism by which NFAT3 blunts migration is by inhibiting 285 LCN2 gene expression (Fougère et al. 2010) . 286
Here, we show that LCN2 expression is required for NFAT1 to increase the invasive 287 capacity of breast cancer cells. We demonstrate that, contrary to NFAT3, NFAT1 binds to 288 regulates independent set of genes as well as, as demonstrated here for LCN2, differentially 295 modulates overlapping gene subsets critical for cell fate, and they underscore the idea that 296 depending on the cell type where they are expressed NFAT isotypes either suppress or 297 promote oncogenic transformation. 298
We also evaluated the mechanisms by which LCN2 modulates breast cancer cell 299 invasion downstream of NFAT1. To this end, we examined the genomic effects of LCN2 300 depletion in order to identify the genes that are similarly regulated by NFAT1 and LCN2. We 301 found that, among 95 genes affected by LCN2 down-regulation, two -TWEAKR 302 (TNFSFR12A) and C6ORF55 (VTA1)-were regulated in the same manner by NFAT1. We 303 focused on TWEAKR because this gene has already been implicated in the motility of TWEAK elicited increase of their chemoinvasive capacity. Surprisingly, when we silenced 311 TWEAKR, invasion was increased and TWEAK could still potentiate this increase. We 312 showed that, in contrast to chemoinvasion, TWEAKR down-regulation inhibited random 313 invasion as reported (Willis et al., 2008) . Therefore, we concluded that, in our chemoinvasion 314 model, TWEAKR was a receptor that mediated an anti-invasive effect and that its cognate 315 ligand, TWEAK, could promote invasion via another, as yet unidentified, receptor the 316 presence of which has already been suggested in RAW264.7 cells (Polek et al. 2003) . Hence, 317
we hypothesised that TWEAK binding to its cognate receptor (TWEAKR) can inhibit 318 invasion and that blocking this association with a TWEAKR-specific neutralising antibody 319 enables TWEAK binding to the other receptor that promotes invasion, but it cannot be ruled 320 out that TWEAK directly enters the cells. Further studies are needed to identify this potential 321 second TWEAK receptor if it exists. We cannot rule out that NFAT1 and LCN2 participate in 322 the regulation of this potential unknown TWEAK receptor. 323
When we examined TWEAK expression in the absence of either LCN2 or NFAT1, we 324 found that it was up-regulated at the protein, but not the mRNA, level. This demonstrates that 325 NFAT1, via LCN2, regulates TWEAK protein expression or stability. In the same manner as 326 for LCN2, inhibiting or silencing TWEAKR elicited up-regulated TWEAK protein expression 327 or availability. This highlights the tight regulation between LCN2 and the 328 TWEAKR/TWEAK axis, all the more so that we found also that TWEAKR and TWEAK can 329 both modulate LCN2 expression at the mRNA and protein levels. Therefore, in breast cancer 330 cells, there exists a subtle equilibrium between LCN2, TWEAKR and TWEAK to modulate 331 the availability of these key factors for the regulation of cell invasion (Fig. 7A) . 332
Since we showed that adding recombinant TWEAK increased the cells' invasive 333 capacity, it was puzzling that elevated TWEAK levels induced by depleting either LCN2 or 334 NFAT1 correlated with a decrease rather than an increase of invasion. Indeed, our study 335
shows that presence of LCN2 is necessary for TWEAK to promote its pro-invasive effect 336 ( Fig. 5D ). Therefore, in the absence of LCN2, TWEAK can only signal by the TWEAKR, 337 and inhibits invasion (Fig. 7B, Without LCN2) . Indeed, when TWEAKR is silenced, TWEAK 338 expression is required to increase invasion and needs the presence of LCN2 ( Fig. 6A and 7B,  339 without TWEAKR). In contrast, in the absence of LCN2, when LCN2 is silenced, TWEAK is 340 an anti-invasive factor (Fig. 6B) . Importantly, this indicates that TWEAK can be either pro- suggesting an equilibrium between the two functions ( Fig. 7B, Equilibrium) . Critically, we 344
show that LCN2 expression up-regulation by NFAT1 is necessary for TWEAK to increase 345 breast cancer cell invasion. Therefore, disturbing this tight equilibrium may be a new entry to 346 inhibit breast cancer cell invasion and ultimately metastasis formation. 
Invasion assays (chemoinvasion and random invasion assays) 426
The chemoinvasion assay was performed essentially as described, using Transwell chambers 427 (Becton Dickinson) with 8-m pore membranes coated with Matrigel (Becton Dickinson). 428
Cells, co-transfected with the relevant expression plasmids and the pCS2-(n)--gal reporter 429 plasmid, were resupsended after 24 hours in serum-free medium containing 0.1% BSA, and 430 cells were added to each well. Conditioned NIH-3T3 medium was added to the bottom wells 431 of the chambers. After 6 hours, cells that had not invaded were removed from the upper face 432 of the filters using cotton swabs, and cells that had invaded to the lower surface of the filters 433 were fixed for 30 min in 4% paraformaldehyde and then stained with PBS containing 1 mg/ml 434 bluo-gal, 2 mM MgCl2, 5 mM potassium ferrocyanide, and 5 mM potassium ferricyanide. 435
All cells in each Transwell were counted. All the counts were normalised by the efficiency of 436 transfection. The numbers of cells that invaded in each condition were compared with 437 the empty vector-transfected condition arbitrary set as a ratio of 1. When the assay was 438 performed with cells transiently transfected by siRNA, cells were stained with crystal violet 439 since 95% of the cells were effectively transfected. In some cases, 200 ng/mL recombinant 440 TWEAK was added for 6 hours to the cells during the assay. 441
The random invasion assay was performed as reported (Willis et al. 2008) . and 50 ng/μL poly(dI-dC)). Unbound probes were separated from DNA-protein complexes in 460 a 5% polyacrylamide gel, and detected after migration on an infrared imaging system 461 ODYSSEY (Li-Cor Biosciences). Super-shift was obtained by incubating nuclear extracts 462 with 0.5 μg antibodies (anti-NFAT1 or IgG control) at room temperature for 20 min before 463 adding the labelled probes. Probe sequences are reported in Supplemental Table 2 . 464
ChIP assay 466
Crosslinking, 48 hr after siRNA transfection, was performed by incubating cells in 1% 467 formaldehyde for 5 min, and stopped by adding 1:7 volume of 1 M glycine for 5 min. After 468 washing, cells were scraped with 1 mL cold PBS. After cell lysis, nuclei were isolated in a 469 first buffer (20 mM HEPES, 10 mM EDTA, 0.5 mM EGTA, 0.25% TritonX100) and then a 470 second (50 mM HEPES, 150 mM NaCl, 1 mM EDTA, 0.5 mM EGTA), each for 10 min at 471 4°C followed by centrifugation. Nuclei pellets were suspended in buffer with 20 mM HEPES, RNA was purified on Qiagen columns, and its integrity was verified using a Bioanalyzer. 500
Total RNA was processed following Roche Nimblegen's instructions to produce double-501 strand DNA and was sent to Roche Nimblegen. Labelling, hybridization, data collection, and 502 normalization were carried out according to NimbleGen protocols. The array used was the 503 human 2006-08-03_HG18_60mer_expression array. Normalised data were then filtered 504 according to their expression level: for a given comparison, average expression of at least one 505 of the two compared experimental conditions had to be 100. For genes targeted by several 506
Nimblegen's probes, the average of probe-normalised intensities was calculated to estimate a 507 single gene signal intensity. We then performed paired Student's t-tests to compare gene 508 expression intensities. Genes were considered significantly differentially regulated when fold-509 change was 1.5 and p-value 0.05. The distance from the gene signal in a given sample to 510 the corresponding average in the 6 samples (MDA-MB-231 cells transfected with si ctrl or si 511 LCN2) was calculated for each LCN2-regulated gene. Corresponding values were displayed 512 and clusterised with MeV4.6.2 from The Institute of Genome Research using Euclidean 513 distance and complete linkage clustering. Full array data are shown in Supplemental Table 1 . B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B 
